Trial Profile

A Phase 1/2 combination clinical trial of TRQ-1501 and KEYTRUDA (pembrolizumab) for the treatment of multiple cancer indications

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 26 Feb 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; TRQ 1501 (Primary)
Indications Bladder cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Sarcoma
Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
Sponsors Torque Therapeutics

Most Recent Events

26 Feb 2019 New trial record
20 Feb 2019 According to a Torque Therapeutics media release, the company will conduct the trial at multiple clinical sites in the U.S. and expects to commence the combination arm of the study with KEYTRUDA later this year.
05 Feb 2019 According to a Torque Therapeutics media release, this trial is expected to begin in early 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com